If you have tried two or more antidepressants for depression and your symptoms still have not lifted, you are not alone - and you are not out of options. Roughly one in three people treated for major depressive disorder in the United States does not achieve full relief with medication alone, a condition clinicians call treatment-resistant depression. For residents of Boca Raton and the broader Palm Beach County area, Transcranial Magnetic Stimulation therapy offers a rigorously studied, FDA-cleared path forward when antidepressants have repeatedly fallen short. This article explains what treatment-resistant depression actually is, what the clinical research shows about TMS in this population, and what the process of getting started looks like at GIA Boca Raton.
What Is Treatment-Resistant Depression?
The most widely accepted clinical definition of treatment-resistant depression is a failure to achieve meaningful symptom improvement after at least two separate antidepressant trials, each at an adequate dose for an adequate duration - typically six to eight weeks at a therapeutic dose. This threshold is used by most insurance carriers, including Medicare, to establish medical necessity for advanced interventions like TMS. If you have tried two medications and neither produced remission, you meet the clinical definition most clinicians and payers use.
Treatment resistance does not mean your depression is untreatable or that something is uniquely wrong with you. It reflects the biological complexity of the condition. The brain's mood-regulating circuitry is not a single switch but a distributed network, and oral medications that travel through the bloodstream and cross the blood-brain barrier reach that circuitry indirectly. For some patients, that indirect route simply does not produce adequate change in the specific cortical regions driving their symptoms.
Common contributors to treatment resistance include:
- Undiagnosed or undertreated co-occurring conditions such as anxiety disorders, ADHD, or chronic pain syndromes
- Thyroid dysfunction or other medical conditions that worsen or mimic depression
- Genetic variations affecting how the body metabolizes specific antidepressants - a field known as pharmacogenomics
- Inadequate prior trials at doses that were too low or durations that were too short to constitute a fair test
- Ongoing psychosocial stressors that medications alone are not designed to resolve
- Active substance use that blunts antidepressant response
A thorough clinical evaluation at our Boca Raton clinic always examines the full picture before recommending TMS, including a detailed review of your prior medication history, dosing, duration of each trial, and any medical factors that may be contributing to your treatment resistance.
Why Medications Often Fall Short After Multiple Trials
The landmark STAR*D trial, a large NIMH-funded study published in the New England Journal of Medicine in 2006, gave clinicians and patients critical real-world data on what happens as patients move through successive antidepressant trials. After a first antidepressant trial, roughly one-third of patients achieved remission. With each subsequent trial, cumulative remission rates climbed but the marginal benefit of each new medication diminished. By the third and fourth treatment levels, the likelihood of achieving remission with any additional antidepressant alone fell substantially - to figures some analyses place at approximately 14 percent or lower at those levels. For current summaries and clinical interpretation of this data, see nimh.nih.gov.
These numbers are not a reason for hopelessness. They are a reason to consider a fundamentally different mechanism of action. TMS bypasses the bloodstream entirely and delivers focused magnetic pulses directly to targeted cortical regions, producing neuronal activation in areas of the brain that are consistently underactive in depression. It works through a completely different biological pathway than any oral antidepressant, which is precisely why patients who have not responded to multiple medications can still respond to TMS.
How TMS Targets the Depressed Brain
The primary target in standard TMS protocols for depression is the left dorsolateral prefrontal cortex, a region of the frontal lobe that governs executive function, emotional regulation, and the initiation of goal-directed behavior. Neuroimaging studies have consistently shown reduced metabolic activity in this region in patients with major depression. High-frequency TMS - typically 10 pulses per second - applied to the left dorsolateral prefrontal cortex increases activity in that area and in connected limbic structures, including the amygdala and the subgenual anterior cingulate cortex, regions known to regulate emotional responsiveness and sustained mood state.
Some protocols add low-frequency stimulation of the right dorsolateral prefrontal cortex at 1 Hz to inhibit a region that research suggests is often overactive in depression, creating a more balanced bilateral effect. Deep TMS systems using the FDA-cleared H-coil technology developed by BrainsWay can reach cortical tissue up to four centimeters below the scalp surface and stimulate a broader cortical network simultaneously, which may be advantageous for patients who have not responded adequately to conventional surface coil protocols.
Theta Burst Stimulation, an accelerated TMS protocol that received FDA clearance for depression, delivers pulses in rapid triplet bursts and can complete a full therapeutic session in approximately three minutes rather than the traditional 19 to 37 minutes. A landmark randomized controlled trial published in The Lancet in 2018 - the THREE-D trial by Blumberger and colleagues - found Theta Burst Stimulation non-inferior to conventional high-frequency TMS in antidepressant efficacy, with a comparable safety profile across more than 400 patients. The dramatically shorter session time is a meaningful practical advantage for working adults in Boca Raton who cannot take an extended break from their schedule five days a week.
What the Research Shows for Treatment-Resistant Depression Specifically
The evidence base for TMS in treatment-resistant populations is now substantial and spans more than two decades of controlled trials and real-world clinical data. The O'Reardon et al. multisite randomized controlled trial published in Biological Psychiatry in 2007 - which formed the foundation of the original FDA clearance - enrolled patients who had failed between one and four antidepressant trials. Active TMS produced statistically significant improvements in depression rating scores compared to sham treatment, with strong effects particularly in patients who had failed fewer prior medications. The trial was specifically designed to reflect the real-world treatment-resistant population rather than idealized research subjects with straightforward clinical histories.
In routine clinical practice outside of tightly controlled trials, real-world response rates in treatment-resistant patients typically range from roughly 50 to 60 percent for meaningful symptom improvement and 30 to 35 percent for full remission, based on published clinical audits and multi-site registry studies. These figures are substantially better than what the STAR*D data showed for additional antidepressant trials in similarly resistant patients, though direct head-to-head comparisons are difficult because patient populations differ across study designs.
Durability of benefit is a natural concern for anyone who has experienced depression returning after prior treatments. A large naturalistic follow-up study published in the Journal of Clinical Psychiatry tracked patients who responded to TMS across a clinical practice network over one year. Approximately 62 percent of respondents remained at or near their post-treatment symptom level without any retreatment during the follow-up period. Those who did relapse frequently responded again to a second TMS course - a meaningful clinical advantage over ECT, which carries cumulative cognitive risks that limit retreatability for some patients. For the most current literature, search PubMed or ask our clinical team for a summary of recent evidence relevant to your specific situation.
TMS Versus Other Options for Treatment-Resistant Depression
Patients who have not responded to multiple antidepressants are frequently offered augmentation strategies, meaning a second agent is added to the existing antidepressant. Common augmentation choices include lithium, atypical antipsychotic medications such as quetiapine or aripiprazole, buspirone, or thyroid hormone supplementation. Each can be effective for some patients. However, for patients who have already struggled with medication side effects - weight gain, sexual dysfunction, emotional blunting, fatigue, cognitive fog - adding more systemic agents to an already burdensome regimen is often an unwelcome prospect and compliance tends to suffer accordingly.
Electroconvulsive therapy (ECT) remains the most acutely effective treatment available for severe, refractory depression and is genuinely lifesaving in specific clinical situations, particularly when a patient is in immediate danger, refusing food, or unable to maintain basic self-care. ECT requires general anesthesia, carries real cognitive side effects including short-term memory disruption that can persist for weeks to months after a course, and must be administered in a hospital or surgical center with full anesthesia support. For patients who are medically stable and whose depression, though persistent, is not immediately life-threatening, TMS is a reasonable intermediate step to try before considering ECT.
Ketamine and esketamine (FDA-approved as Spravato) produce rapid antidepressant effects, often within hours of the first infusion, making them valuable tools for patients in acute suicidal crisis or those who need rapid relief while a longer-acting treatment takes hold. The durability of ketamine response beyond the initial infusion series varies substantially across patients and remains an active area of investigation. Spravato requires administration in a certified healthcare setting with mandatory post-dose observation. Some patients benefit from using ketamine and TMS sequentially - ketamine for rapid acute stabilization followed by TMS for sustained, durable effect - and this combined approach is being formally evaluated in ongoing research.
TMS occupies a distinctive position in the treatment-resistant landscape: it is non-systemic, meaning no drug circulates through your body; non-invasive, meaning no anesthesia, no needles, and no sedation; performed entirely in an outpatient office setting without any procedure room or recovery area; and covered by most major insurance plans once clinical criteria are met. For the typical Boca Raton patient who has tried several medications without adequate relief and wants to avoid the risks and burden associated with more aggressive interventions, TMS is generally the logical next step after augmentation strategies have been exhausted or declined.
The Treatment Protocol at Our Boca Raton Clinic
Your first appointment at GIA Boca Raton is a comprehensive psychiatric evaluation, not a TMS session. Our clinician reviews your full history - prior diagnoses, every medication you have tried at what dose and for how long, any therapy you have received, relevant medical conditions, and your current symptom profile - and discusses whether TMS is clinically appropriate for your situation. If it is, we proceed with insurance verification and prior authorization before scheduling your first treatment session. We do not begin treatment until we have confirmed your coverage and explained your out-of-pocket costs clearly.
A standard FDA-cleared TMS course for depression consists of 36 sessions delivered five days a week over approximately seven weeks, though some clinical protocols use 30 sessions over six weeks. Each session lasts between 3 and 40 minutes depending on the specific protocol selected for you. You sit in a reclining chair, fully awake and clothed. A trained technician positions the TMS coil precisely against the left side of your scalp and calibrates the pulse intensity to your individual motor threshold - the minimum field strength needed to produce a visible twitch in your thumb - which is determined at your first treatment session and used to personalize all subsequent sessions.
During treatment you will hear a series of rapid clicking sounds and feel a rhythmic tapping sensation on your scalp. Most patients describe this as mildly uncomfortable during the first few sessions and essentially unremarkable by the second week. You remain completely alert throughout - many patients read, listen to a podcast, or simply relax in the chair. When the session ends you walk directly out of the office and drive yourself home or back to work. There is no recovery period, no impairment of any kind, and no restriction on activities for the rest of your day.
Our clinical team conducts formal symptom assessments using validated rating scales at regular intervals throughout your course, typically every two weeks. These structured check-ins allow us to monitor your trajectory quantitatively and, when appropriate, discuss adjustments to stimulation parameters or session frequency. After your initial course, we collaborate with you on a personalized maintenance plan - some patients benefit from periodic booster sessions every few weeks or months, while others remain symptom-free for a year or longer without any additional TMS treatment.
Who Is a Good Candidate for TMS in Boca Raton?
TMS therapy for depression is FDA-cleared for adults diagnosed with major depressive disorder who have not achieved satisfactory improvement from prior antidepressant medications. Beyond the core diagnostic requirement, good candidates typically share some combination of the following characteristics:
- Have not achieved adequate symptom relief from one or more antidepressant medications at adequate doses for adequate durations
- Have experienced intolerable side effects from antidepressants that limited their ability to continue those medications
- Have medical reasons to minimize systemic medication load, such as complex drug interactions in older adults managing multiple chronic conditions
- Are pregnant or planning to become pregnant and wish to avoid pharmacological treatment during that period; TMS carries no known fetal risk from magnetic field exposure, though the treating OB should always be part of any care decision
- Prefer a non-pharmacological treatment approach and have discussed this preference with a clinician in the context of their specific clinical situation
TMS is not appropriate for patients with ferromagnetic metal implants in or near the skull, including cochlear implants, certain intracranial aneurysm clips, or metal fragments in the brain from prior injury. A personal history of seizure disorder is not an absolute contraindication in all circumstances but requires careful individual evaluation and full clinical disclosure before TMS can proceed. Patients with implanted cardiac devices such as pacemakers or defibrillators should consult with their cardiologist as part of the pre-TMS evaluation process.
Insurance Coverage and Costs in Florida
TMS coverage has expanded substantially over the past decade, and most patients in Boca Raton who meet clinical criteria will find that their insurance covers TMS therapy. Medicare Part B covers TMS for major depressive disorder in Florida through Palmetto GBA, the Medicare Administrative Contractor for this region. Most major commercial carriers - Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and others - have formal TMS coverage policies in place. The specific clinical criteria each plan applies, particularly the number of prior antidepressant failures required for authorization and the documentation format accepted, differ by plan and are updated periodically. Always verify your current benefits directly with your carrier rather than relying on general descriptions of coverage.
Our Boca Raton billing team conducts a complete benefits verification before your first TMS session. We document your prior treatment history in the format required to satisfy your insurer's prior authorization standards and submit that authorization on your behalf. Most patients who meet their plan's criteria receive authorization within one to three weeks. We communicate with you clearly throughout that process so you understand your anticipated out-of-pocket exposure before any treatment begins - there are no billing surprises after the fact.
Patients without insurance coverage or with plans that exclude TMS sometimes ask about self-pay pricing. Fees for a complete TMS course vary by provider and change over time; contact our office directly for current pricing rather than relying on figures you may find online. Some patients find that the cost of a complete TMS course is comparable to months of cumulative medication costs, therapy co-pays, and productivity losses associated with undertreated depression - though that comparison depends heavily on individual circumstances and insurance situations. Our team is glad to help you think through the financial picture as part of your initial consultation at no obligation.
TMS as Part of a Comprehensive Mental Wellness Plan
At GIA Boca Raton, TMS is never delivered in isolation from the rest of a patient's care. The research on treatment-resistant depression consistently points to better long-term outcomes when biological interventions like TMS are integrated with psychotherapy, lifestyle modification, and treatment of any co-occurring conditions. Addressing the neurobiological dimensions of depression with TMS while simultaneously working on cognitive patterns, behavioral activation, and stress management with a therapist produces more durable remission than either approach alone, according to the weight of available clinical evidence.
We coordinate care to ensure that if you are currently working with a therapist, they are kept informed of your progress during your TMS course. If you are not in therapy and would benefit from it, we can assist in connecting you with therapists in the Boca Raton and Palm Beach County area who have experience supporting patients through a TMS course. Sleep quality, regular physical exercise, and nutrition each have documented relationships with neuroplasticity and with the likelihood of maintaining TMS-induced improvements over time, and our clinical team discusses these factors with you as part of building your individualized treatment plan.
For patients whose treatment-resistant depression is intertwined with substance use - a common and clinically important pairing that our team encounters regularly - we bring our addiction and dual-diagnosis expertise to bear simultaneously. Active alcohol or substance use significantly reduces TMS response rates and must be addressed as part of any effective plan, not deferred until after the TMS course is complete.
Why Boca Raton Patients Choose GIA for Treatment-Resistant Depression
Palm Beach County has a high density of mental health providers, and patients researching TMS in Boca Raton have genuine options. The meaningful difference at GIA Boca Raton is the integration of TMS within a comprehensive mental wellness program staffed by psychiatrists, therapists, and addiction specialists who collaborate on each patient's care. TMS here is not a standalone procedure administered by technicians in a clinical vacuum - it is one component of a coordinated clinical plan that addresses your full picture, including your history, your co-occurring conditions, and your life circumstances.
We serve patients from throughout Palm Beach County, including Delray Beach, Boynton Beach, Deerfield Beach, and Pompano Beach, with appointment availability designed to minimize disruption to your work schedule or daily routine. For working professionals, morning and early afternoon slots allow TMS sessions to fit before the workday begins or during a lunch break. The brevity of Theta Burst sessions in particular - approximately three minutes of active stimulation - makes the logistics of a five-day-a-week treatment course genuinely manageable for most schedules.
Boca Raton also has a large and growing senior population, and we have particular clinical experience with older adults navigating treatment-resistant depression. Elderly patients frequently carry a high existing medication burden from multiple chronic medical conditions, and TMS - which introduces no new drug to the body and produces no systemic side effects such as weight gain, cardiac effects, or drug interactions - is often the intervention that finally produces sustained mood improvement without compounding an already complex pharmacological situation. If you are an adult child helping an aging parent who has not responded to antidepressants, a consultation with our team is a worthwhile next step.
Frequently Asked Questions
How many antidepressants do I need to have tried before qualifying for TMS therapy?
The minimum is typically two adequate antidepressant trials, meaning each medication was taken at a therapeutic dose for at least six to eight weeks without achieving remission. Most commercial insurance plans and Medicare require documentation of these prior trials, though some plans require three or four failed trials. Our team reviews your full medication history and determines your eligibility based on your specific insurer's current criteria before submitting a prior authorization request on your behalf.
Does Medicare or private insurance cover TMS for treatment-resistant depression in Florida?
Yes, Medicare Part B and the major private carriers operating in Florida - including Florida Blue, Aetna, Cigna, and UnitedHealthcare - have TMS coverage policies for patients with major depressive disorder who meet clinical criteria. Coverage requirements and prior authorization rules vary by plan and are updated periodically. We recommend verifying your benefits directly with your carrier and also allowing our billing team to conduct a no-cost formal verification before treatment begins.
How soon will I feel a difference from TMS treatment?
Most patients who respond to TMS begin noticing changes between the third and fifth week of treatment, though some report improvements as early as the second week and others do not notice significant improvement until the full course is complete or shortly after. Response patterns vary individually, which is why we conduct formal symptom assessments at regular intervals throughout your course. If no change is apparent by week four or five, our clinical team discusses whether protocol adjustments might improve your trajectory.
Can I continue taking my antidepressant medication during TMS?
In most cases, yes. Many patients undergo TMS while continuing a current antidepressant, and some evidence suggests this combination produces better outcomes than TMS alone in certain patients. Your prescribing psychiatrist and our clinical team will coordinate to determine whether any medication adjustments make sense before, during, or after your TMS course. Never stop or change a medication without guidance from your prescriber.
Is TMS therapy painful or uncomfortable?
TMS is not painful for most patients, though the tapping sensation on the scalp can be uncomfortable during the first few sessions while your scalp adjusts and the clinical team calibrates intensity to your motor threshold. Mild headache during or shortly after a session is the most commonly reported side effect and typically resolves within an hour. Discomfort usually diminishes significantly after the first week. There is no sedation, no anesthesia, and no recovery time - patients drive themselves to and from every session.
What are my options if TMS does not produce adequate relief?
A subset of treatment-resistant patients do not respond to an initial TMS course, and we do not simply discharge those patients. The clinical conversation shifts to whether protocol adjustments - such as targeting a different cortical region, using a deep TMS coil, or switching to an accelerated Theta Burst protocol - might produce a different result. Further options include ketamine or esketamine therapy, ECT for severe or immediately dangerous presentations, MAOI antidepressants, or enrollment in a clinical trial. We work with you to identify a viable next step rather than leaving you without a plan.
Schedule a Consultation at GIA Boca Raton
If antidepressants have not given you the sustained relief you deserve, a conversation with our clinical team costs you nothing and could open a genuinely new path forward. Reach out through our contact page to schedule a free initial consultation. We will review your history, answer your questions honestly, and give you a clear clinical assessment of whether TMS is the right fit for where you are right now.